CY1111926T1 - Συνεργιστικες συνθεσεις με fk-228 - Google Patents

Συνεργιστικες συνθεσεις με fk-228

Info

Publication number
CY1111926T1
CY1111926T1 CY20111100965T CY111100965T CY1111926T1 CY 1111926 T1 CY1111926 T1 CY 1111926T1 CY 20111100965 T CY20111100965 T CY 20111100965T CY 111100965 T CY111100965 T CY 111100965T CY 1111926 T1 CY1111926 T1 CY 1111926T1
Authority
CY
Cyprus
Prior art keywords
antitumor
agent
tumor
antitumor agent
activity
Prior art date
Application number
CY20111100965T
Other languages
Greek (el)
English (en)
Inventor
Yoshinori Naoe
Takeshi Inoue
Yasuhiko Kano
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY1111926T1 publication Critical patent/CY1111926T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20111100965T 2004-02-25 2011-10-10 Συνεργιστικες συνθεσεις με fk-228 CY1111926T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004050520 2004-02-25
US56607704P 2004-04-29 2004-04-29
EP05719967A EP1718322B1 (en) 2004-02-25 2005-02-25 Synergistic compositions with fk-228

Publications (1)

Publication Number Publication Date
CY1111926T1 true CY1111926T1 (el) 2015-11-04

Family

ID=34889383

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100965T CY1111926T1 (el) 2004-02-25 2011-10-10 Συνεργιστικες συνθεσεις με fk-228

Country Status (11)

Country Link
US (2) US7951780B2 (https=)
EP (1) EP1718322B1 (https=)
JP (1) JP4930055B2 (https=)
AT (1) ATE516041T1 (https=)
CA (1) CA2557540A1 (https=)
CY (1) CY1111926T1 (https=)
DK (1) DK1718322T3 (https=)
PL (1) PL1718322T3 (https=)
PT (1) PT1718322E (https=)
SI (1) SI1718322T1 (https=)
WO (1) WO2005079827A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4238728B2 (ja) * 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
US8673888B2 (en) * 2002-04-05 2014-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Depsipeptide for therapy of kidney cancer
EP1595952A4 (en) * 2003-02-19 2008-05-21 Astellas Pharma Inc METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
DK2596801T3 (en) * 2006-10-06 2018-08-13 Bavarian Nordic As RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
AU2007342028B2 (en) * 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
WO2010036404A2 (en) * 2008-05-09 2010-04-01 University Of Maryland, Baltimore Novel retinamide retinoic acid metabolism blocking agents
EP2366398A1 (en) * 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
JP6031437B2 (ja) * 2010-06-07 2016-11-24 アブラクシス バイオサイエンス， エルエルシー 増殖性疾患を処置するための組み合わせ療法
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN106860872B (zh) * 2017-01-18 2019-03-22 上海交通大学 用于逆转肿瘤对铂类抗癌药多药耐药性的两亲性药-药纳米颗粒药物及其制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0315810A (ja) * 1989-06-13 1991-01-24 Minolta Camera Co Ltd カメラ
CA2308565A1 (en) * 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
JP2003513912A (ja) * 1999-11-10 2003-04-15 ワーナー−ランバート・カンパニー 組合せ化学療法
CN1414971A (zh) * 1999-12-08 2003-04-30 埃克斯西特治疗公司 用作免疫抑制剂的缩肽及其同类物
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
WO2002020817A1 (en) 2000-09-01 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. A method of producing fr901228
DK1355566T3 (da) * 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6620816B2 (en) * 2001-04-26 2003-09-16 Bristol-Myers Squibb Company Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
JP4238728B2 (ja) 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
SK1102004A3 (sk) * 2001-08-31 2005-05-05 Bristol-Myers Squibb Company Liečivo na liečenie proliferačných ochorení a farmaceutická kompozícia na liečenie rakoviny
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US8673888B2 (en) 2002-04-05 2014-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Depsipeptide for therapy of kidney cancer
AU2003226408B2 (en) 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
EP1595952A4 (en) 2003-02-19 2008-05-21 Astellas Pharma Inc METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
SI2238982T1 (sl) 2003-06-27 2013-01-31 Astellas Pharma Inc. Terapevtsko sredstvo za mehkotkivni sarkom
CA2472842C (en) 2003-07-22 2012-05-29 Honda Motor Co., Ltd. Working machine
ES2425083T3 (es) 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent

Also Published As

Publication number Publication date
CA2557540A1 (en) 2005-09-01
US8822422B2 (en) 2014-09-02
DK1718322T3 (da) 2011-08-29
PT1718322E (pt) 2011-09-05
US7951780B2 (en) 2011-05-31
US20110160295A1 (en) 2011-06-30
WO2005079827A2 (en) 2005-09-01
JP4930055B2 (ja) 2012-05-09
EP1718322A2 (en) 2006-11-08
PL1718322T3 (pl) 2011-12-30
US20050187149A1 (en) 2005-08-25
ATE516041T1 (de) 2011-07-15
WO2005079827A3 (en) 2005-12-08
EP1718322B1 (en) 2011-07-13
JP2007524650A (ja) 2007-08-30
SI1718322T1 (sl) 2011-09-30

Similar Documents

Publication Publication Date Title
CY1111926T1 (el) Συνεργιστικες συνθεσεις με fk-228
CY1122861T1 (el) Φαρμακευτικες συνθεσεις της αμορφης μορφης ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου
CY1108344T1 (el) Φορεις εκφρασης που περιεχουν τον mcmv ie2 υποκινητη
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
NO20062420L (no) Anvendelse av IAP-oligomer og et kjemoterapeutisk middel for behandling av proliferative sykdommer
NO20081636L (no) FAP - inhibitorer
DK3090748T3 (da) Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
EA200701918A1 (ru) Белок липокалин
CY1115580T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης
ITMI20030709A1 (it) Miscele di stabilizzanti.
EA200701790A1 (ru) Твёрдый фармацевтический дозированный состав
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
DK1447011T3 (da) Morgenmadscerealier
DE602005013568D1 (de) Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate
FI20021822A0 (fi) Elintarvike
ITRM20020296A0 (it) Sale di creatina ad aumento potere nutrizionale, antiossidante e terapeutico e composizioni che lo contengono.
GT200400113A (es) Productos aril-heteroaromaticos, composiciones que los contienen y su utilizacion.
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
ATE450273T1 (de) Proliferationshemmendes arzneimittel
EP1758996A4 (en) Antisense oligonucleotides against CPLA2, compositions and applications thereof
ATE427656T1 (de) Getreidekírner behandelt mit wassrigen rhodentizid-formulierungen
CY1115894T1 (el) Χρησεις ιντερφερονων με τροποποιημενη χωρικη δομη
ITRM20040143A1 (it) Sale di creatina ad aumentato valore nutrizionale e terapeutico e composizioni che lo contengono.